Stomach Cancer Treatment Market Size, Share & Industry Analysis, By Drug Type (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, and Others), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST)), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI102094

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Prevalence of Stomach Cancer – For Key Countries
2. Regulatory Scenario - For Key Countries/Regions
3. Reimbursement Scenario - For Key Countries/Regions
4. New Product Launches
5. Key Industry Developments - Mergers, Acquisitions and Partnerships
Global Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub-region
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub regions
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub region
  1. South Africa
  2. GCC
  3. Rest of Middle East & Africa
Competitive Analysis
1. Key Industry Developments
2. Global Market Share Analysis (2024)
3. Company Profiles (Overview, Drug Types & Services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  1. Eli Lilly and Company
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  2. F. Hoffmann-La Roche Ltd.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  3. Merck & Co., Inc.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  4. Novartis AG
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  5. Bayer AG
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  6. Celltrion Inc.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  7. Bristol-Myers Squibb Company
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  8. TAIHO PHARMACEUTICAL CO., LTD.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  9. Ipsen Pharma
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  10. Jiangsu Hengrui Medicine Co., Ltd
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability).
  11. Other Prominent Players
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
Strategic Recommendations

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Prevalence of Stomach Cancer – For Key Countries
2. Regulatory Scenario - For Key Countries/Regions
3. Reimbursement Scenario - For Key Countries/Regions
4. New Product Launches
5. Key Industry Developments - Mergers, Acquisitions and Partnerships
Global Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub-region
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub regions
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Analysis, Insights and Forecast, 2019-2032
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Type
  1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
  2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
  3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Gastric Adenocarcinoma
  2. Gastrointestinal Stromal Tumor (GIST)
  3. Gastric Neuroendocrine Tumor (gNET)
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
6. Market Analysis, Insights and Forecast – By Countries/ Sub region
  1. South Africa
  2. GCC
  3. Rest of Middle East & Africa
Competitive Analysis
1. Key Industry Developments
2. Global Market Share Analysis (2024)
3. Company Profiles (Overview, Drug Types & Services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  1. Eli Lilly and Company
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  2. F. Hoffmann-La Roche Ltd.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  3. Merck & Co., Inc.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  4. Novartis AG
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  5. Bayer AG
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  6. Celltrion Inc.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  7. Bristol-Myers Squibb Company
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  8. TAIHO PHARMACEUTICAL CO., LTD.
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  9. Ipsen Pharma
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  10. Jiangsu Hengrui Medicine Co., Ltd
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability).
  11. Other Prominent Players
    1. Overview,
    2. Drug Types & Services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
Strategic Recommendations

Read Less

List of Figures

Figure 1: Global Stomach Cancer/Gastric Cancer Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2024 & 2032

Figure 2: Global Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Drug Type, 2024 & 2032

Figure 3: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Programmed Cell Death Protein 1 (PD-1) Inhibitors, 2019-2032

Figure 4: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Human Epidermal Growth Factor Receptor (HER2) Antagonists, 2019-2032

Figure 5: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists, 2019-2032

Figure 6: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Others, 2019-2032

Figure 7: Global Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Disease Indication, 2024 & 2032

Figure 8: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Gastric Adenocarcinoma, 2019-2032

Figure 9: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Gastrointestinal Stromal Tumor (GIST), 2019-2032

Figure 10: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Gastric Neuroendocrine Tumors (gNET), 2019-2032

Figure 11: Global Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Route of Administration, 2024 & 2032

Figure 12: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Oral, 2019-2032

Figure 13: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Parenteral, 2019-2032

Figure 14: Global Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 15: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Hospital Pharmacy, 2019-2032

Figure 16: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Retail Pharmacy, 2019-2032

Figure 17: Global Stomach Cancer/Gastric Cancer Treatment Market Forecast (US$ Mn), by Online Pharmacy, 2019-2032

Figure 18: Global Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Region, 2024 & 2032

Figure 19: North America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Drug Type, 2024 & 2032

Figure 20: North America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Drug Type, 2024

Figure 21: North America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Disease Indication, 2024 & 2032

Figure 22: North America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Disease Indication, 2024

Figure 23: North America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Route of Administration, 2024 & 2032

Figure 24: North America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Route of Administration, 2024

Figure 25: North America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Distribution Channel, 2024 & 2032

Figure 26: North America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 27: North America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), By Country, 2024 & 2032

Figure 28: North America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), By Country, 2024

Figure 29: Europe Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Drug Type, 2024 & 2032

Figure 30: Europe Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Drug Type, 2024

Figure 31: Europe Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Disease Indication, 2024 & 2032

Figure 32: Europe Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Disease Indication, 2024

Figure 33: Europe Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Route of Administration, 2024 & 2032

Figure 34: Europe Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Route of Administration, 2024

Figure 35: Europe Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Distribution Channel, 2024 & 2032

Figure 36: Europe Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 37: Europe Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), By Country/ Sub-region, 2024 & 2032

Figure 38: Europe Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 39: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Drug Type, 2024 & 2032

Figure 40: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Drug Type, 2024

Figure 41: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Disease Indication, 2024 & 2032

Figure 42: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Disease Indication, 2024

Figure 43: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Route of Administration, 2024 & 2032

Figure 44: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Route of Administration, 2024

Figure 45: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Distribution Channel, 2024 & 2032

Figure 46: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 47: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), By Country/ Sub-region, 2024 & 2032

Figure 48: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 49: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Drug Type, 2024 & 2032

Figure 50: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Drug Type, 2024

Figure 51: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Disease Indication, 2024 & 2032

Figure 52: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Disease Indication, 2024

Figure 53: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Route of Administration, 2024 & 2032

Figure 54: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Route of Administration, 2024

Figure 55: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Distribution Channel, 2024 & 2032

Figure 56: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 57: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), By Country/ Sub-region, 2024 & 2032

Figure 58: Latin America Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 59: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Drug Type, 2024 & 2032

Figure 60: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Drug Type, 2024

Figure 61: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Disease Indication, 2024 & 2032

Figure 62: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Disease Indication, 2024

Figure 63: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Route of Administration, 2024 & 2032

Figure 64: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Route of Administration, 2024

Figure 65: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), by Distribution Channel, 2024 & 2032

Figure 66: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 67: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value (US$ Mn), By Country/ Sub-region, 2024 & 2032

Figure 68: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 69: Global Stomach Cancer/Gastric Cancer Treatment Market Share (%), By Company, 2024

List of Tables

Table 1: Global Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Drug Type, 2015–2026

Table 2: Global Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Disease Indication, 2015–2026

Table 3: Global Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2015–2026

Table 4: Global Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015–2026

Table 5: Global Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Region, 2019-2032

Table 6: North America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Drug Type, 2019-2032

Table 7: North America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Disease Indication, 2019-2032

Table 8: North America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2019-2032

Table 9: North America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2019-2032

Table 10: North America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Country, 2019-2032

Table 11: Europe Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Drug Type, 2019-2032

Table 12: Europe Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Disease Indication, 2019-2032

Table 13: Europe Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2019-2032

Table 14: Europe Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2019-2032

Table 15: Europe Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Country/ Sub-region, 2019-2032

Table 16: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Drug Type, 2019-2032

Table 17: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Disease Indication, 2019-2032

Table 18: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2019-2032

Table 19: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2019-2032

Table 20: Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Country/ Sub-region, 2019-2032

Table 21: Latin America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Drug Type, 2019-2032

Table 22: Latin America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Disease Indication, 2019-2032

Table 23: Latin America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2019-2032

Table 24: Latin America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2019-2032

Table 25: Latin America Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Country/ Sub-region, 2019-2032

Table 26: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Drug Type, 2019-2032

Table 27: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Disease Indication, 2019-2032

Table 28: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2019-2032

Table 29: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2019-2032

Table 30: Middle East & Africa Stomach Cancer/Gastric Cancer Treatment Market Revenue (US$ Mn) Forecast, by Country/ Sub-region, 2019-2032

Stomach-Gastric- Cancer- Treatment Market

STUDY PERIOD: 2019-2032
BASE YEAR: 2024
HISTORICAL DATA: 2019-2023
NO OF PAGES: 130

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com